tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate | 1240912-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate
• 英文别名: tert-Butyl 2-(tetrahydro-2H-pyran-3-yl)hydrazinecarboxylate；tert-butyl N-(oxan-3-ylamino)carbamate
• CAS: 1240912-22-4
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: FOBVQYVABFGEAZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate 在 盐酸 、 copper(l) iodide 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 L-脯氨酸 作用下， 以 二甲基亚砜 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-methoxy-1-(tetrahydro-2H-pyran-3-yl)-1,2-dihydro-3H-pyrazolo[4,3-c]pyridin-3-one
  参考文献：
  名称：

  EP2857400

  摘要：

  公开号：
• 作为产物：
  描述：

  四氢-2H-吡喃-3-酮 在 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 4.5h， 生成 tert-butyl 2-(oxan-3-yl)hydrazine-1-carboxylate
  参考文献：
  名称：

  1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 Inhibitors

  摘要：

  本发明提供了式(I)的1,5-二氢-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氢-4H-吡唑并[4,3-c]吡啶-4-酮作为PDE1抑制剂，并将它们用作药物，特别用于治疗神经退行性疾病和精神疾病。

  公开号：

  US20170291901A1

文献信息

• [EN] PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE PYRAZOLO[4,3-C]CINNOLIN-3-ONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010096338A1

  公开（公告）日：2010-08-26

  The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]咖啉-3-酮化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• [EN] HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS D'UN RÉCEPTEUR M1 DE CINNOLINE FUSIONNÉE HÉTÉROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010123716A1

  公开（公告）日：2010-10-28

  The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的杂环融合喹啉化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物。
• [EN] N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE<br/>[FR] PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES N-SULFONYLÉS ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ABBVIE S Á R L

  公开号：WO2017060874A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R5和R6具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。
• PYRAZOLOQUINOLINE DERIVATIVES
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20130143907A1

  公开（公告）日：2013-06-06

  A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R 1 is a hydrogen atom; R 2 is an aromatic ring group, etc.; R 3 is a hydrogen atom, etc; R 4 is a hydrogen atom; R 5 is an oxepanyl group, etc.; R 6 is a hydrogen atom.

  由以下化学式（I）表示的化合物和/或药理学上可接受的盐具有PDE9抑制作用，因此预期将提高脑内cGMP浓度。PDE9抑制作用和cGMP的增加导致学习和记忆行为的改善，化合物（I）具有作为治疗代理人用于阿尔茨海默病认知功能障碍的适用性。其中R1是氢原子；R2是芳香环基团等；R3是氢原子等；R4是氢原子；R5是氧杂环丙基团等；R6是氢原子。